XML 36 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2021202020212020
Medicare19 %20 %19 %21 %
Medicare Advantage13 %11 %13 %11 %
Blue Shield12 %12 %12 %12 %
Janssen (SIMPONI®)
*13 %*12 %
*Less than 10%.
 Accounts Receivable
 September 30, 2021December 31, 2020
 
Blue Shield17 %11 %
United Healthcare16 %*
Janssen (SIMPONI®)
11 %35 %
*Less than 10%.
Disaggregation of Revenue The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Revenue:
Healthcare insurers$6,910 $5,749 $20,318 $15,949 
Government2,330 2,184 6,733 6,236 
Client(1)2,346 1,260 6,738 3,088 
Other(2)265 235 821 636 
Janssen (SIMPONI®)
400 1,347 1,000 3,398 
Total revenue$12,251 $10,775 $35,610 $29,307 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Restricted Cash and Cash Equivalents Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands): 
 September 30, 2021December 31, 2020
 
Cash and cash equivalents$106,766 $57,448 
Restricted cash100 100 
$106,866 $57,548 
Schedule of Cash and Cash Equivalents Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands): 
 September 30, 2021December 31, 2020
 
Cash and cash equivalents$106,766 $57,448 
Restricted cash100 100 
$106,866 $57,548 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Warrants to purchase common stock409,108 426,827 409,108 426,827 
Common stock options2,067,057 1,975,250 2,067,057 1,975,250 
Restricted stock units403,100 — 403,100 — 
Employee stock purchase plan4,130 3,144 4,130 3,144 
Total2,883,395 2,405,221 2,883,395 2,405,221